Lactobacillus rhamnosus GG: современные возможности применения в пульмонологии, нефрологии, аллергологии, детской гастроэнтерологической практике
Lactobacillus rhamnosus GG: современные возможности применения в пульмонологии, нефрологии, аллергологии, детской гастроэнтерологической практике
Захарова И.Н., Борзова Е.Ю., Симакова М.А. Lactobacillus rhamnosus GG: современные возможности применения в пульмонологии, нефрологии, аллергологии, детской гастроэнтерологической практике. Педиатрия. Consilium Medicum. 2019; 3: 52–60.
DOI: 10.26442/26586630.2019.3.190601
________________________________________________
DOI: 10.26442/26586630.2019.3.190601
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Пробиотики исторически рассматривались как лекарственные препараты или пищевые добавки, способные предупреждать либо помогать лечить некоторые заболевания желудочно-кишечного тракта. Однако в исследованиях на моделях животных, дальнейших исследованиях, проведенных у взрослых и детей, установлено положительное иммунологическое, метаболическое влияние определенных штаммов не только при гастроэнтерологической патологии, но и при заболеваниях других органов и систем. В настоящее время проводится большое количество исследований, показывающих негативное влияние нарушений состава микробиома определенных участков нашего организма на риск формирования и течение различных заболеваний. Нормальный микробиом кишечника влияет практически на все аспекты здоровья человека, но степень доказательности научных данных, используемых технологий, а также понимание механизмов действия значительно варьируют в различных исследованиях. Лактобациллы являются представителями здоровой микробиоты человека. Было показано положительное влияние штамма Lactobacillus rhamnosus GG (LGG) на иммунный ответ организма. Наибольший интерес исследователей в последние 40 лет отмечается к изучению этого пробиотического штамма в отношении профилактики и лечения многих заболеваний. В статье собраны данные о применении LGG с целью профилактики респираторных инфекций, инфекций мочевых путей, кариеса, лечения инфекционных и антибиотикоассоциированных диарей, неалкогольной жировой болезни печени, а также предварительные данные исследования LGG в комбинации с Bifidobacterium lactis Bb-12 у детей с впервые выявленным сахарным диабетом 1-го типа.
Ключевые слова: Lactobacillus rhamnosus GG, пробиотики, кишечная микробиота, дети, профилактика, терапия.
Key words: Lactobacillus rhamnosus GG, probiotics, intestinal microbiota, children, prevention, therapy.
Ключевые слова: Lactobacillus rhamnosus GG, пробиотики, кишечная микробиота, дети, профилактика, терапия.
________________________________________________
Key words: Lactobacillus rhamnosus GG, probiotics, intestinal microbiota, children, prevention, therapy.
Список литературы
1. Capurso L. Thirty Years of Lactobacillus rhamnosus GG: A Review. J Clin Gastroenterol 2019; 53: 1–41. DOI: 10.1097/mcg.0000000000001170
2. Segers ME, Lebeer S. Towards a better understanding of Lactobacillus rhamnosus GG – host interactions. Microbial Cell Factories 2014; 13 (Suppl. 1): 7. DOI: 10.1186/1475-2859-13-s1-s7
3. Lu R, Fasano S, Madayiputhiya N et al. Isolation, Identification, and Characterization of Small Bioactive Peptides From Lactobacillus GG Conditional Media That Exert Both Anti-Gram-negative and Gram-positive Bactericidal Activity. J Pediatr Gastroenterol Nutr 2009; 49 (1): 23–30. DOI: 10.1097/mpg.0b013e3181924d1e
4. Vélez MP, Petrova MI, Lebeer S et al. Characterization of MabA, a modulator of Lactobacillus rhamnosus GG adhesion and biofilm formation. FEMS Immunol Med Microbiol 2010; 59 (3): 386–98. DOI: 10.1111/j.1574-695x.2010.00680.x
5. Landersjo C, Yang Z, Huttunen E, Widmalm G. Structural studies of the exopolysaccharide produced by Lactobacillus rhamnosus strain GG (ATCC 53103). Biomacromolecules 2002; 3: 880–4.
6. Wang Y, Liu L, Moore DJ et al. An LGG-derived protein promotes IgA production through upregulation of APRIL expression in intestinal epithelial cells. Mucosal Immunol 2016; 10 (2): 373–84. DOI: 10.1038/mi.2016.57
7. Claes IJ, Segers ME, Verhoeven TL et al. Lipoteichoic acid is an important microbe-associated molecular pattern of Lactobacillus rhamnosus GG. Microb Cell Fact 2012; 11: 161. DOI: 10.1186/1475-2859-11-161
8. Van Baarlen P, Troost FJ, Van der Meer C et al. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. PNAS 2011; 108: 4562–9. DOI: 10.1073/pnas.1000079107
9. Bron PA, van Baarlen P, Kleerebezem M. Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nature Rev Microbiol 2011; 10 (1): 66–78. DOI: 10.1038/nrmicro2690
10. Korterink J, Devanarayana NM, Rajindrajith S et al. Childhood functional abdominal pain: mechanisms and management. Nat Rev Gastroenterol Hepatol 2015; 12 (3): 159–71. https: //doi.org/10.1038/nrgastro.2015.21
11. GBD Diarrhoeal Diseases Collaborators. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study. Lancet Infect Dis 2017; 17: 909–48. Erratum in: Lancet Infect Dis 2017; 17: 897.
12. Huang J, Bousvaros A, Lee J et al. Efficacy of probiotic use in acute diarrhea in children, a meta-analysis. Dig Dis Sci 2002; 47 (11): 2625–34.
13. Guarino A, Ashkenazi S, Gendrel D et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr 2014; 59: 132–52.
14. Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. Cochrane Database System Rev 2010. Issue 11. Art. No.: CD003048. DOI: 10.1002/14651858.CD003048.pub3
15. Szajewska H, Kołodziej M, Gieruszczak‐Białek D et al. Systematic review with meta‐analysis: Lactobacillus rhamnosus GG for treating acute gastroenteritis in children – a 2019 update. Aliment Pharmacol Ther 2019; 49: 1376–84.
16. Arvola T, Laiho K, Torkkeli S et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics 1999; 104: 64.
17. Johnston BC, Supina AL, Vohra S. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. CMAJ 2006; 175 (4): 377–83.
18. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101: 812–22.
19. Johnston BC, Goldenberg JZ, Vandvik PO et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2011; 11: CD004827. DOI: 10.1002/14651858.CD004827.pub3
20. Goldenberg JZ, Lytvyn L, Steurich J et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2015; 12: CD004827.
21. Szajewska H, Canani RB, Guarino A et al. ESPGHAN Working Group for Probiotics Prebiotics. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. J Pediatr Gastroenterol Nutr 2016; 62 (3): 495–506. DOI: 10.1097/MPG.0000000000001081
22. Guo Q, Goldenberg JZ, Humphrey C et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2019; 4: CD004827. DOI: 10.1002/14651858.CD004827.pub5
23. Abarca-Gómez L, Abdeen ZA, Hamid ZA et al. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet 2017; 390 (10113): 2627–42. DOI: 10.1016/S0140-6736 (17)32129-3
24. Kumar S, Kelly AS. Review of Childhood Obesity. Mayo Clinic Proceedings 2017; 92 (2): 251–65. DOI: 10.1016/j.mayocp.2016.09.017
25. Machado MV, Cortez-Pinto H. Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol 2012; 11: 440–9.
26. Frost G, Sleeth ML, Sahuri-Arisoylu M et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun 2014; 5: 3611.
27. Zhu L, Baker SS, Gill C et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013; 57: 601–9.
28. Zhang H, DiBaise JK, Zuccolo A et al. Human gut microbiota in obesity and after gastric bypass. P Natl Acad Sci USA 2009; 106: 2365–70.
29. Michail S, Lin M, Frey MR et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol 2014; 91 (2): 1–9. DOI: 10.1093/femsec/fiu002
30. Vajro P, Mandato C, Licenziati MR et al. Effects of Lactobacillus rhamnosus Strain GG in Pediatric Obesity-related Liver Disease. J Pediatr Gastroenterol Nutr 2011; 52 (6): 740–3. DOI: 10.1097/mpg.0b013e31821f9b85
31. Sharpton SR, Maraj B, Harding-Theobald E et al. Gut microbiome – targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Am J Clin Nutr 2019; 110 (1): 139–49. DOI: 10.1093/ajcn/nqz042
32. Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. Genome Med 2016; 8: 51.
33. Man WH, de Steenhuijsen Piters WAA, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nature Rev Microbiol 2017; 15 (5): 259–70. DOI: 10.1038/nrmicro.2017.14
34. Esposito S, Principi N. Impact of nasopharyngeal microbiota on the development of respiratory tract diseases. Eur J Clin Microbiol Infect Dis 2017; 37 (1): 1–7. DOI: 10.1007/s10096-017-3076-7
35. Hatakka K, Savilahti E, Ponka A et al. Effect of long-term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ 2001; 322 (7298): 1327.
36. Hojsak I, Snovak N, Abdovic S et al. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial. Clin Nutr 2010; 29 (3): 312–6.
37. Rautava S, Salminen S, Isolauri E. Specific probiotics in reducing the risk of acute infections in infancy – a randomised, double-blind, placebo-controlled study. Br J Nutr 2009; 101 (11): 1722–6.
38. Liu S, Hu P, Du X et al. Lactobacillus rhamnosus GG supplementation for preventing respiratory infections in children: a meta-analysis of randomized, placebo-controlled trials. Indian Pediatr 2013; 50: 377–81.
39. Hao Q, Dong BR, Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev 2015; 2: CD006895.
40. Laursen RP, Hojsak I. Probiotics for respiratory tract infections in children attending day care centers – a systematic review. Eur J Pediatr 2018; 177 (7): 979–94. DOI: 10.1007/s00431-018-3167-1
41. Kumpu M, Kekkonen RA, Kautiainen H et al. Milk containing probiotic Lactobacillus rhamnosus GG and respiratory illness in children: a randomized, double-blind, placebo-controlled trial. Eur J Clin Nutr 2012; 66: 1020–3. DOI: doi.org/10.1038/ejcn. 2012.62
42. Scott AM, Clark J, Julien B et al. Probiotics for preventing acute otitis media in children. Cochrane Database Syst Rev 2019; Issue 6. Art. No.: CD012941. DOI: 10.1002/14651858.CD012941.pub2
43. Van den Broek MFL, De Boeck I, Claes IJJ et al. Multifactorial inhibition of lactobacilli against the respiratory tract pathogen Moraxella catarrhalis. Benef Microb 2018; 9 (3): 429–39. DOI: 10.3920/bm2017.0101
44. Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database System Rev 2015; Issue 12. Art. No.: CD008772. DOI: 10.1002/14651858.cd008772.pub2
45. Kara SS, Volkan B, Erten I. Lactobacillus rhamnosus GG can protect malnourished children. Benef Microb 2019; 10 (3): 237–44. DOI: 10.3920/BM2018.0071
46. http: //raaci.ru/education/clinic_recomendations/97.html
47. Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med 2005; 352: 2314–24.
48. Mastrorilli C, Caffarelli C, Hoffmann-Sommergruber K. Food allergy and atopic dermatitis: Prediction, progression, and prevention. Pediatr Allergy Immunol 2017; 28 (8): 831–40. DOI: 10.1111/pai.12831
49. Zhao W, Ho H, Bunyavanich S. The Gut Microbiome in Food Allergy. Ann Allergy, Asthma Immunol 2018; 122 (3): 276–82. DOI: 10.1016/j.anai.2018.12.012
50. Pascal M, Perez-Gordo M, Caballero T et al. Microb Allergic Dis Front Immunol 2018; 9: 1584. DOI: 10.3389/fimmu.2018.01584
51. Cosenza L, Nocerino R, Di Scala C et al. Bugs for atopy: the Lactobacillus rhamnosus GG strategy for food allergy prevention and treatment in children. Benef Microb 2015; 6 (2): 225–32. DOI: 10.3920/bm2014.0158
52. Isolauri E. Studies on Lactobacillus GG in food hypersensitivity disorders. Nutr Today (Suppl.) 1996; 31: 285–315.
53. Kalliomaki M, Salminen S, Arvilommi H et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001; 357: 1076–9. DOI: 10.1016/S0140-6736 (00)04259-8
54. Kalliomaki M, Salminen S, Poussa T et al. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003; 361: 1869–71. DOI: 10.1016/S0140-6736 (03)13490-3
55. Kalliomaki M, Salminen S, Poussa T, Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo- controlled trial. J Allergy Clin Immunol 2007; 119: 1019–21. DOI: 10.1016/j. jaci.2006.12.608
56. Rautava S, Kalliomaki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immnomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol 2002; 109 (1): 119–21.
57. Kalliomäki M, Antoine JM, Herz U et al. Guidance for Substantiating the Evidence for Beneficial Effects of Probiotics: Prevention and Management of Allergic Diseases by Probiotics. J Nutr 2010; 140 (3): 713S–721S. DOI: 10.3945/jn.109.113761
58. Fiocchi A, Pawankar R, Cuello-Garcia C et al. World allergy organization-McMaster university guidelines for allergic disease prevention (GLAD-P): Probiotics. World Allergy Organ J 2015; 8 (1): 4.
59. Szajewska H, Horvath A. Lactobacillus rhamnosus GG in the Primary Prevention of Eczema in Children: A Systematic Review and Meta-Analysis. Nutrients 2018; 10 (9): 1319. DOI: 10.3390/nu10091319
60. Berni Canani R, Di Costanzo M, Pezzella V et al. The potential therapeutic efficacy of Lactobacillus GG in children with food allergies. Pharmaceuticals 2012; 5: 655–64.
61. Murch SH. Toll of allergy reduced by probiotics. Lancet 2001; 357: 1057–9.
62. Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. J Allergy Clin Immunol 1997; 99 (2): 179–85.
63. Isolauri E, Arvola T, Sutas Y et al. Probiotics in the management of atopic eczema. Clin Exp Allergy 2000; 30 (11): 1604–10.
64. Rosenfeldt V, Benfeldt E, Nielsen SD et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 2003; 111 (2): 389–95. DOI: 10.1067/mai.2003.389
65. Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic Bacteria in the Management of Atopic Disease: Underscoring the Importance of Viability. J Pediatr Gastroenterol Nutr 2003; 36 (2): 223–7. DOI: 10.1097/00005176-200302000-00012
66. Viljanen M, Savilahti E, Haahtela T et al. Probiotics in the treatment of atopic eczema/ dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy 2005; 60: 494–500. DOI: 10.1111/j.1398-9995.2004.00514.x
67. Brouwer ML, Wolt-Plompen SAA, Dubois AEJ et al. No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. Clin Exper Allergy 2006; 36 (7): 899–906. DOI: 10.1111/j.1365-2222.2006.02513.x
68. Fölster-Holst R, Müller F, Schnopp N et al. Prospective, randomized controlled trial on Lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis. Br J Dermatol 2006; 155 (6): 1256–61. DOI: 10.1111/j.1365-2133.2006.07558.x
69. Grüber C, Wendt M, Sulser C et al. Randomized, placebo-controlled trial of Lactobacillus rhamnosus GG as treatment of atopic dermatitis in infancy. Allergy 2007; 62 (11): 1270–6. DOI: 10.1111/j.1398-9995.2007.01543.x
70. Baldassarre ME, Laforgia N, Fanelli M et al. Lactobacillus GG improve recovery in infants with blood in the stools and presumptive allergic colitis compared with extensively hydrolyzed formula alone. J Pediatr 2010; 156: 397–401.
71. Berni Canani R, Di Costanzo M, Bedogni G et al. Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG reduces the occurrence of other allergic manifestations in children with cow’s milk allergy: 3-year randomized controlled trial. J Allergy Clin Immunol 2017; 139 (6): 1906–13. DOI: 10.1016/j.jaci.2016.10.050
72. Qamer S, Deshmukh M, Patole S. Probiotics for cow’s milk protein allergy: a systematic review of randomized controlled trials. Eur J Pediatr 2019; 178 (8): 1139–49. DOI: 10.1007/s00431-019-03397-6
73. Nase L, Hatakka K, Savilahti E et al. Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. Caries Res 2001; 35 (6): 412–20.
74. Schwendicke F, Dörfer C, Kneist S et al. Cariogenic Effects of Probiotic Lactobacillus rhamnosus GG in a Dental Biofilm Model. Caries Res 2014; 48 (3): 186–92. DOI: 10.1159/000355907
75. Gungor OE, Kirzioglu Z, Kivanc M. Probiotics: can they be used to improve oral health? Benef Microb 2015; 6 (5): 647–56. DOI: 10.3920/bm2014.0167
76. Knip M, Siljander H. The role of the intestinal microbiota in type 1 diabetes mellitus. Nat Rev Endocrinol 2016; 12: 154–67. DOI: 10.1038/nrendo.2015.218
77. Vatanen T, Franzosa EA, Schwager R et al. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. Nature 2018; 562 (7728): 589–94. DOI: 10.1038/s41586-018-0620-2
78. Groele L, Szajewska H, Szypowska A. Effects of Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 on beta-cell function in children with newly diagnosed type 1 diabetes: protocol of a randomised controlled trial. BMJ Open 2017; 7 (10): e017178. DOI: 10.1136/bmjopen-2017-017178
79. Abstracts for the 44th Annual Meeting of the International Society for Pediatric and Adolescent Diabetes (ISPAD), 11–14 October 2018, Hyderabad, India, Vol. 19, Issue S26: 33. doi.org/10.1111/pedi.12745
2. Segers ME, Lebeer S. Towards a better understanding of Lactobacillus rhamnosus GG – host interactions. Microbial Cell Factories 2014; 13 (Suppl. 1): 7. DOI: 10.1186/1475-2859-13-s1-s7
3. Lu R, Fasano S, Madayiputhiya N et al. Isolation, Identification, and Characterization of Small Bioactive Peptides From Lactobacillus GG Conditional Media That Exert Both Anti-Gram-negative and Gram-positive Bactericidal Activity. J Pediatr Gastroenterol Nutr 2009; 49 (1): 23–30. DOI: 10.1097/mpg.0b013e3181924d1e
4. Vélez MP, Petrova MI, Lebeer S et al. Characterization of MabA, a modulator of Lactobacillus rhamnosus GG adhesion and biofilm formation. FEMS Immunol Med Microbiol 2010; 59 (3): 386–98. DOI: 10.1111/j.1574-695x.2010.00680.x
5. Landersjo C, Yang Z, Huttunen E, Widmalm G. Structural studies of the exopolysaccharide produced by Lactobacillus rhamnosus strain GG (ATCC 53103). Biomacromolecules 2002; 3: 880–4.
6. Wang Y, Liu L, Moore DJ et al. An LGG-derived protein promotes IgA production through upregulation of APRIL expression in intestinal epithelial cells. Mucosal Immunol 2016; 10 (2): 373–84. DOI: 10.1038/mi.2016.57
7. Claes IJ, Segers ME, Verhoeven TL et al. Lipoteichoic acid is an important microbe-associated molecular pattern of Lactobacillus rhamnosus GG. Microb Cell Fact 2012; 11: 161. DOI: 10.1186/1475-2859-11-161
8. Van Baarlen P, Troost FJ, Van der Meer C et al. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. PNAS 2011; 108: 4562–9. DOI: 10.1073/pnas.1000079107
9. Bron PA, van Baarlen P, Kleerebezem M. Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nature Rev Microbiol 2011; 10 (1): 66–78. DOI: 10.1038/nrmicro2690
10. Korterink J, Devanarayana NM, Rajindrajith S et al. Childhood functional abdominal pain: mechanisms and management. Nat Rev Gastroenterol Hepatol 2015; 12 (3): 159–71. https: //doi.org/10.1038/nrgastro.2015.21
11. GBD Diarrhoeal Diseases Collaborators. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study. Lancet Infect Dis 2017; 17: 909–48. Erratum in: Lancet Infect Dis 2017; 17: 897.
12. Huang J, Bousvaros A, Lee J et al. Efficacy of probiotic use in acute diarrhea in children, a meta-analysis. Dig Dis Sci 2002; 47 (11): 2625–34.
13. Guarino A, Ashkenazi S, Gendrel D et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr 2014; 59: 132–52.
14. Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. Cochrane Database System Rev 2010. Issue 11. Art. No.: CD003048. DOI: 10.1002/14651858.CD003048.pub3
15. Szajewska H, Kołodziej M, Gieruszczak‐Białek D et al. Systematic review with meta‐analysis: Lactobacillus rhamnosus GG for treating acute gastroenteritis in children – a 2019 update. Aliment Pharmacol Ther 2019; 49: 1376–84.
16. Arvola T, Laiho K, Torkkeli S et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics 1999; 104: 64.
17. Johnston BC, Supina AL, Vohra S. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. CMAJ 2006; 175 (4): 377–83.
18. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101: 812–22.
19. Johnston BC, Goldenberg JZ, Vandvik PO et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2011; 11: CD004827. DOI: 10.1002/14651858.CD004827.pub3
20. Goldenberg JZ, Lytvyn L, Steurich J et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2015; 12: CD004827.
21. Szajewska H, Canani RB, Guarino A et al. ESPGHAN Working Group for Probiotics Prebiotics. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. J Pediatr Gastroenterol Nutr 2016; 62 (3): 495–506. DOI: 10.1097/MPG.0000000000001081
22. Guo Q, Goldenberg JZ, Humphrey C et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2019; 4: CD004827. DOI: 10.1002/14651858.CD004827.pub5
23. Abarca-Gómez L, Abdeen ZA, Hamid ZA et al. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet 2017; 390 (10113): 2627–42. DOI: 10.1016/S0140-6736 (17)32129-3
24. Kumar S, Kelly AS. Review of Childhood Obesity. Mayo Clinic Proceedings 2017; 92 (2): 251–65. DOI: 10.1016/j.mayocp.2016.09.017
25. Machado MV, Cortez-Pinto H. Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol 2012; 11: 440–9.
26. Frost G, Sleeth ML, Sahuri-Arisoylu M et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun 2014; 5: 3611.
27. Zhu L, Baker SS, Gill C et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013; 57: 601–9.
28. Zhang H, DiBaise JK, Zuccolo A et al. Human gut microbiota in obesity and after gastric bypass. P Natl Acad Sci USA 2009; 106: 2365–70.
29. Michail S, Lin M, Frey MR et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol 2014; 91 (2): 1–9. DOI: 10.1093/femsec/fiu002
30. Vajro P, Mandato C, Licenziati MR et al. Effects of Lactobacillus rhamnosus Strain GG in Pediatric Obesity-related Liver Disease. J Pediatr Gastroenterol Nutr 2011; 52 (6): 740–3. DOI: 10.1097/mpg.0b013e31821f9b85
31. Sharpton SR, Maraj B, Harding-Theobald E et al. Gut microbiome – targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Am J Clin Nutr 2019; 110 (1): 139–49. DOI: 10.1093/ajcn/nqz042
32. Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. Genome Med 2016; 8: 51.
33. Man WH, de Steenhuijsen Piters WAA, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nature Rev Microbiol 2017; 15 (5): 259–70. DOI: 10.1038/nrmicro.2017.14
34. Esposito S, Principi N. Impact of nasopharyngeal microbiota on the development of respiratory tract diseases. Eur J Clin Microbiol Infect Dis 2017; 37 (1): 1–7. DOI: 10.1007/s10096-017-3076-7
35. Hatakka K, Savilahti E, Ponka A et al. Effect of long-term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ 2001; 322 (7298): 1327.
36. Hojsak I, Snovak N, Abdovic S et al. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial. Clin Nutr 2010; 29 (3): 312–6.
37. Rautava S, Salminen S, Isolauri E. Specific probiotics in reducing the risk of acute infections in infancy – a randomised, double-blind, placebo-controlled study. Br J Nutr 2009; 101 (11): 1722–6.
38. Liu S, Hu P, Du X et al. Lactobacillus rhamnosus GG supplementation for preventing respiratory infections in children: a meta-analysis of randomized, placebo-controlled trials. Indian Pediatr 2013; 50: 377–81.
39. Hao Q, Dong BR, Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev 2015; 2: CD006895.
40. Laursen RP, Hojsak I. Probiotics for respiratory tract infections in children attending day care centers – a systematic review. Eur J Pediatr 2018; 177 (7): 979–94. DOI: 10.1007/s00431-018-3167-1
41. Kumpu M, Kekkonen RA, Kautiainen H et al. Milk containing probiotic Lactobacillus rhamnosus GG and respiratory illness in children: a randomized, double-blind, placebo-controlled trial. Eur J Clin Nutr 2012; 66: 1020–3. DOI: doi.org/10.1038/ejcn. 2012.62
42. Scott AM, Clark J, Julien B et al. Probiotics for preventing acute otitis media in children. Cochrane Database Syst Rev 2019; Issue 6. Art. No.: CD012941. DOI: 10.1002/14651858.CD012941.pub2
43. Van den Broek MFL, De Boeck I, Claes IJJ et al. Multifactorial inhibition of lactobacilli against the respiratory tract pathogen Moraxella catarrhalis. Benef Microb 2018; 9 (3): 429–39. DOI: 10.3920/bm2017.0101
44. Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database System Rev 2015; Issue 12. Art. No.: CD008772. DOI: 10.1002/14651858.cd008772.pub2
45. Kara SS, Volkan B, Erten I. Lactobacillus rhamnosus GG can protect malnourished children. Benef Microb 2019; 10 (3): 237–44. DOI: 10.3920/BM2018.0071
46. http: //raaci.ru/education/clinic_recomendations/97.html
47. Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med 2005; 352: 2314–24.
48. Mastrorilli C, Caffarelli C, Hoffmann-Sommergruber K. Food allergy and atopic dermatitis: Prediction, progression, and prevention. Pediatr Allergy Immunol 2017; 28 (8): 831–40. DOI: 10.1111/pai.12831
49. Zhao W, Ho H, Bunyavanich S. The Gut Microbiome in Food Allergy. Ann Allergy, Asthma Immunol 2018; 122 (3): 276–82. DOI: 10.1016/j.anai.2018.12.012
50. Pascal M, Perez-Gordo M, Caballero T et al. Microb Allergic Dis Front Immunol 2018; 9: 1584. DOI: 10.3389/fimmu.2018.01584
51. Cosenza L, Nocerino R, Di Scala C et al. Bugs for atopy: the Lactobacillus rhamnosus GG strategy for food allergy prevention and treatment in children. Benef Microb 2015; 6 (2): 225–32. DOI: 10.3920/bm2014.0158
52. Isolauri E. Studies on Lactobacillus GG in food hypersensitivity disorders. Nutr Today (Suppl.) 1996; 31: 285–315.
53. Kalliomaki M, Salminen S, Arvilommi H et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001; 357: 1076–9. DOI: 10.1016/S0140-6736 (00)04259-8
54. Kalliomaki M, Salminen S, Poussa T et al. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003; 361: 1869–71. DOI: 10.1016/S0140-6736 (03)13490-3
55. Kalliomaki M, Salminen S, Poussa T, Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo- controlled trial. J Allergy Clin Immunol 2007; 119: 1019–21. DOI: 10.1016/j. jaci.2006.12.608
56. Rautava S, Kalliomaki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immnomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol 2002; 109 (1): 119–21.
57. Kalliomäki M, Antoine JM, Herz U et al. Guidance for Substantiating the Evidence for Beneficial Effects of Probiotics: Prevention and Management of Allergic Diseases by Probiotics. J Nutr 2010; 140 (3): 713S–721S. DOI: 10.3945/jn.109.113761
58. Fiocchi A, Pawankar R, Cuello-Garcia C et al. World allergy organization-McMaster university guidelines for allergic disease prevention (GLAD-P): Probiotics. World Allergy Organ J 2015; 8 (1): 4.
59. Szajewska H, Horvath A. Lactobacillus rhamnosus GG in the Primary Prevention of Eczema in Children: A Systematic Review and Meta-Analysis. Nutrients 2018; 10 (9): 1319. DOI: 10.3390/nu10091319
60. Berni Canani R, Di Costanzo M, Pezzella V et al. The potential therapeutic efficacy of Lactobacillus GG in children with food allergies. Pharmaceuticals 2012; 5: 655–64.
61. Murch SH. Toll of allergy reduced by probiotics. Lancet 2001; 357: 1057–9.
62. Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. J Allergy Clin Immunol 1997; 99 (2): 179–85.
63. Isolauri E, Arvola T, Sutas Y et al. Probiotics in the management of atopic eczema. Clin Exp Allergy 2000; 30 (11): 1604–10.
64. Rosenfeldt V, Benfeldt E, Nielsen SD et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 2003; 111 (2): 389–95. DOI: 10.1067/mai.2003.389
65. Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic Bacteria in the Management of Atopic Disease: Underscoring the Importance of Viability. J Pediatr Gastroenterol Nutr 2003; 36 (2): 223–7. DOI: 10.1097/00005176-200302000-00012
66. Viljanen M, Savilahti E, Haahtela T et al. Probiotics in the treatment of atopic eczema/ dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy 2005; 60: 494–500. DOI: 10.1111/j.1398-9995.2004.00514.x
67. Brouwer ML, Wolt-Plompen SAA, Dubois AEJ et al. No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. Clin Exper Allergy 2006; 36 (7): 899–906. DOI: 10.1111/j.1365-2222.2006.02513.x
68. Fölster-Holst R, Müller F, Schnopp N et al. Prospective, randomized controlled trial on Lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis. Br J Dermatol 2006; 155 (6): 1256–61. DOI: 10.1111/j.1365-2133.2006.07558.x
69. Grüber C, Wendt M, Sulser C et al. Randomized, placebo-controlled trial of Lactobacillus rhamnosus GG as treatment of atopic dermatitis in infancy. Allergy 2007; 62 (11): 1270–6. DOI: 10.1111/j.1398-9995.2007.01543.x
70. Baldassarre ME, Laforgia N, Fanelli M et al. Lactobacillus GG improve recovery in infants with blood in the stools and presumptive allergic colitis compared with extensively hydrolyzed formula alone. J Pediatr 2010; 156: 397–401.
71. Berni Canani R, Di Costanzo M, Bedogni G et al. Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG reduces the occurrence of other allergic manifestations in children with cow’s milk allergy: 3-year randomized controlled trial. J Allergy Clin Immunol 2017; 139 (6): 1906–13. DOI: 10.1016/j.jaci.2016.10.050
72. Qamer S, Deshmukh M, Patole S. Probiotics for cow’s milk protein allergy: a systematic review of randomized controlled trials. Eur J Pediatr 2019; 178 (8): 1139–49. DOI: 10.1007/s00431-019-03397-6
73. Nase L, Hatakka K, Savilahti E et al. Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. Caries Res 2001; 35 (6): 412–20.
74. Schwendicke F, Dörfer C, Kneist S et al. Cariogenic Effects of Probiotic Lactobacillus rhamnosus GG in a Dental Biofilm Model. Caries Res 2014; 48 (3): 186–92. DOI: 10.1159/000355907
75. Gungor OE, Kirzioglu Z, Kivanc M. Probiotics: can they be used to improve oral health? Benef Microb 2015; 6 (5): 647–56. DOI: 10.3920/bm2014.0167
76. Knip M, Siljander H. The role of the intestinal microbiota in type 1 diabetes mellitus. Nat Rev Endocrinol 2016; 12: 154–67. DOI: 10.1038/nrendo.2015.218
77. Vatanen T, Franzosa EA, Schwager R et al. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. Nature 2018; 562 (7728): 589–94. DOI: 10.1038/s41586-018-0620-2
78. Groele L, Szajewska H, Szypowska A. Effects of Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 on beta-cell function in children with newly diagnosed type 1 diabetes: protocol of a randomised controlled trial. BMJ Open 2017; 7 (10): e017178. DOI: 10.1136/bmjopen-2017-017178
79. Abstracts for the 44th Annual Meeting of the International Society for Pediatric and Adolescent Diabetes (ISPAD), 11–14 October 2018, Hyderabad, India, Vol. 19, Issue S26: 33. doi.org/10.1111/pedi.12745
2. Segers ME, Lebeer S. Towards a better understanding of Lactobacillus rhamnosus GG – host interactions. Microbial Cell Factories 2014; 13 (Suppl. 1): 7. DOI: 10.1186/1475-2859-13-s1-s7
3. Lu R, Fasano S, Madayiputhiya N et al. Isolation, Identification, and Characterization of Small Bioactive Peptides From Lactobacillus GG Conditional Media That Exert Both Anti-Gram-negative and Gram-positive Bactericidal Activity. J Pediatr Gastroenterol Nutr 2009; 49 (1): 23–30. DOI: 10.1097/mpg.0b013e3181924d1e
4. Vélez MP, Petrova MI, Lebeer S et al. Characterization of MabA, a modulator of Lactobacillus rhamnosus GG adhesion and biofilm formation. FEMS Immunol Med Microbiol 2010; 59 (3): 386–98. DOI: 10.1111/j.1574-695x.2010.00680.x
5. Landersjo C, Yang Z, Huttunen E, Widmalm G. Structural studies of the exopolysaccharide produced by Lactobacillus rhamnosus strain GG (ATCC 53103). Biomacromolecules 2002; 3: 880–4.
6. Wang Y, Liu L, Moore DJ et al. An LGG-derived protein promotes IgA production through upregulation of APRIL expression in intestinal epithelial cells. Mucosal Immunol 2016; 10 (2): 373–84. DOI: 10.1038/mi.2016.57
7. Claes IJ, Segers ME, Verhoeven TL et al. Lipoteichoic acid is an important microbe-associated molecular pattern of Lactobacillus rhamnosus GG. Microb Cell Fact 2012; 11: 161. DOI: 10.1186/1475-2859-11-161
8. Van Baarlen P, Troost FJ, Van der Meer C et al. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. PNAS 2011; 108: 4562–9. DOI: 10.1073/pnas.1000079107
9. Bron PA, van Baarlen P, Kleerebezem M. Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nature Rev Microbiol 2011; 10 (1): 66–78. DOI: 10.1038/nrmicro2690
10. Korterink J, Devanarayana NM, Rajindrajith S et al. Childhood functional abdominal pain: mechanisms and management. Nat Rev Gastroenterol Hepatol 2015; 12 (3): 159–71. https: //doi.org/10.1038/nrgastro.2015.21
11. GBD Diarrhoeal Diseases Collaborators. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study. Lancet Infect Dis 2017; 17: 909–48. Erratum in: Lancet Infect Dis 2017; 17: 897.
12. Huang J, Bousvaros A, Lee J et al. Efficacy of probiotic use in acute diarrhea in children, a meta-analysis. Dig Dis Sci 2002; 47 (11): 2625–34.
13. Guarino A, Ashkenazi S, Gendrel D et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr 2014; 59: 132–52.
14. Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. Cochrane Database System Rev 2010. Issue 11. Art. No.: CD003048. DOI: 10.1002/14651858.CD003048.pub3
15. Szajewska H, Kołodziej M, Gieruszczak‐Białek D et al. Systematic review with meta‐analysis: Lactobacillus rhamnosus GG for treating acute gastroenteritis in children – a 2019 update. Aliment Pharmacol Ther 2019; 49: 1376–84.
16. Arvola T, Laiho K, Torkkeli S et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics 1999; 104: 64.
17. Johnston BC, Supina AL, Vohra S. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. CMAJ 2006; 175 (4): 377–83.
18. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101: 812–22.
19. Johnston BC, Goldenberg JZ, Vandvik PO et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2011; 11: CD004827. DOI: 10.1002/14651858.CD004827.pub3
20. Goldenberg JZ, Lytvyn L, Steurich J et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2015; 12: CD004827.
21. Szajewska H, Canani RB, Guarino A et al. ESPGHAN Working Group for Probiotics Prebiotics. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. J Pediatr Gastroenterol Nutr 2016; 62 (3): 495–506. DOI: 10.1097/MPG.0000000000001081
22. Guo Q, Goldenberg JZ, Humphrey C et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2019; 4: CD004827. DOI: 10.1002/14651858.CD004827.pub5
23. Abarca-Gómez L, Abdeen ZA, Hamid ZA et al. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet 2017; 390 (10113): 2627–42. DOI: 10.1016/S0140-6736 (17)32129-3
24. Kumar S, Kelly AS. Review of Childhood Obesity. Mayo Clinic Proceedings 2017; 92 (2): 251–65. DOI: 10.1016/j.mayocp.2016.09.017
25. Machado MV, Cortez-Pinto H. Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol 2012; 11: 440–9.
26. Frost G, Sleeth ML, Sahuri-Arisoylu M et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun 2014; 5: 3611.
27. Zhu L, Baker SS, Gill C et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013; 57: 601–9.
28. Zhang H, DiBaise JK, Zuccolo A et al. Human gut microbiota in obesity and after gastric bypass. P Natl Acad Sci USA 2009; 106: 2365–70.
29. Michail S, Lin M, Frey MR et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol 2014; 91 (2): 1–9. DOI: 10.1093/femsec/fiu002
30. Vajro P, Mandato C, Licenziati MR et al. Effects of Lactobacillus rhamnosus Strain GG in Pediatric Obesity-related Liver Disease. J Pediatr Gastroenterol Nutr 2011; 52 (6): 740–3. DOI: 10.1097/mpg.0b013e31821f9b85
31. Sharpton SR, Maraj B, Harding-Theobald E et al. Gut microbiome – targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Am J Clin Nutr 2019; 110 (1): 139–49. DOI: 10.1093/ajcn/nqz042
32. Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. Genome Med 2016; 8: 51.
33. Man WH, de Steenhuijsen Piters WAA, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nature Rev Microbiol 2017; 15 (5): 259–70. DOI: 10.1038/nrmicro.2017.14
34. Esposito S, Principi N. Impact of nasopharyngeal microbiota on the development of respiratory tract diseases. Eur J Clin Microbiol Infect Dis 2017; 37 (1): 1–7. DOI: 10.1007/s10096-017-3076-7
35. Hatakka K, Savilahti E, Ponka A et al. Effect of long-term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ 2001; 322 (7298): 1327.
36. Hojsak I, Snovak N, Abdovic S et al. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial. Clin Nutr 2010; 29 (3): 312–6.
37. Rautava S, Salminen S, Isolauri E. Specific probiotics in reducing the risk of acute infections in infancy – a randomised, double-blind, placebo-controlled study. Br J Nutr 2009; 101 (11): 1722–6.
38. Liu S, Hu P, Du X et al. Lactobacillus rhamnosus GG supplementation for preventing respiratory infections in children: a meta-analysis of randomized, placebo-controlled trials. Indian Pediatr 2013; 50: 377–81.
39. Hao Q, Dong BR, Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev 2015; 2: CD006895.
40. Laursen RP, Hojsak I. Probiotics for respiratory tract infections in children attending day care centers – a systematic review. Eur J Pediatr 2018; 177 (7): 979–94. DOI: 10.1007/s00431-018-3167-1
41. Kumpu M, Kekkonen RA, Kautiainen H et al. Milk containing probiotic Lactobacillus rhamnosus GG and respiratory illness in children: a randomized, double-blind, placebo-controlled trial. Eur J Clin Nutr 2012; 66: 1020–3. DOI: doi.org/10.1038/ejcn. 2012.62
42. Scott AM, Clark J, Julien B et al. Probiotics for preventing acute otitis media in children. Cochrane Database Syst Rev 2019; Issue 6. Art. No.: CD012941. DOI: 10.1002/14651858.CD012941.pub2
43. Van den Broek MFL, De Boeck I, Claes IJJ et al. Multifactorial inhibition of lactobacilli against the respiratory tract pathogen Moraxella catarrhalis. Benef Microb 2018; 9 (3): 429–39. DOI: 10.3920/bm2017.0101
44. Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database System Rev 2015; Issue 12. Art. No.: CD008772. DOI: 10.1002/14651858.cd008772.pub2
45. Kara SS, Volkan B, Erten I. Lactobacillus rhamnosus GG can protect malnourished children. Benef Microb 2019; 10 (3): 237–44. DOI: 10.3920/BM2018.0071
46. http: //raaci.ru/education/clinic_recomendations/97.html
47. Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med 2005; 352: 2314–24.
48. Mastrorilli C, Caffarelli C, Hoffmann-Sommergruber K. Food allergy and atopic dermatitis: Prediction, progression, and prevention. Pediatr Allergy Immunol 2017; 28 (8): 831–40. DOI: 10.1111/pai.12831
49. Zhao W, Ho H, Bunyavanich S. The Gut Microbiome in Food Allergy. Ann Allergy, Asthma Immunol 2018; 122 (3): 276–82. DOI: 10.1016/j.anai.2018.12.012
50. Pascal M, Perez-Gordo M, Caballero T et al. Microb Allergic Dis Front Immunol 2018; 9: 1584. DOI: 10.3389/fimmu.2018.01584
51. Cosenza L, Nocerino R, Di Scala C et al. Bugs for atopy: the Lactobacillus rhamnosus GG strategy for food allergy prevention and treatment in children. Benef Microb 2015; 6 (2): 225–32. DOI: 10.3920/bm2014.0158
52. Isolauri E. Studies on Lactobacillus GG in food hypersensitivity disorders. Nutr Today (Suppl.) 1996; 31: 285–315.
53. Kalliomaki M, Salminen S, Arvilommi H et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001; 357: 1076–9. DOI: 10.1016/S0140-6736 (00)04259-8
54. Kalliomaki M, Salminen S, Poussa T et al. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003; 361: 1869–71. DOI: 10.1016/S0140-6736 (03)13490-3
55. Kalliomaki M, Salminen S, Poussa T, Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo- controlled trial. J Allergy Clin Immunol 2007; 119: 1019–21. DOI: 10.1016/j. jaci.2006.12.608
56. Rautava S, Kalliomaki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immnomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol 2002; 109 (1): 119–21.
57. Kalliomäki M, Antoine JM, Herz U et al. Guidance for Substantiating the Evidence for Beneficial Effects of Probiotics: Prevention and Management of Allergic Diseases by Probiotics. J Nutr 2010; 140 (3): 713S–721S. DOI: 10.3945/jn.109.113761
58. Fiocchi A, Pawankar R, Cuello-Garcia C et al. World allergy organization-McMaster university guidelines for allergic disease prevention (GLAD-P): Probiotics. World Allergy Organ J 2015; 8 (1): 4.
59. Szajewska H, Horvath A. Lactobacillus rhamnosus GG in the Primary Prevention of Eczema in Children: A Systematic Review and Meta-Analysis. Nutrients 2018; 10 (9): 1319. DOI: 10.3390/nu10091319
60. Berni Canani R, Di Costanzo M, Pezzella V et al. The potential therapeutic efficacy of Lactobacillus GG in children with food allergies. Pharmaceuticals 2012; 5: 655–64.
61. Murch SH. Toll of allergy reduced by probiotics. Lancet 2001; 357: 1057–9.
62. Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. J Allergy Clin Immunol 1997; 99 (2): 179–85.
63. Isolauri E, Arvola T, Sutas Y et al. Probiotics in the management of atopic eczema. Clin Exp Allergy 2000; 30 (11): 1604–10.
64. Rosenfeldt V, Benfeldt E, Nielsen SD et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 2003; 111 (2): 389–95. DOI: 10.1067/mai.2003.389
65. Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic Bacteria in the Management of Atopic Disease: Underscoring the Importance of Viability. J Pediatr Gastroenterol Nutr 2003; 36 (2): 223–7. DOI: 10.1097/00005176-200302000-00012
66. Viljanen M, Savilahti E, Haahtela T et al. Probiotics in the treatment of atopic eczema/ dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy 2005; 60: 494–500. DOI: 10.1111/j.1398-9995.2004.00514.x
67. Brouwer ML, Wolt-Plompen SAA, Dubois AEJ et al. No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. Clin Exper Allergy 2006; 36 (7): 899–906. DOI: 10.1111/j.1365-2222.2006.02513.x
68. Fölster-Holst R, Müller F, Schnopp N et al. Prospective, randomized controlled trial on Lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis. Br J Dermatol 2006; 155 (6): 1256–61. DOI: 10.1111/j.1365-2133.2006.07558.x
69. Grüber C, Wendt M, Sulser C et al. Randomized, placebo-controlled trial of Lactobacillus rhamnosus GG as treatment of atopic dermatitis in infancy. Allergy 2007; 62 (11): 1270–6. DOI: 10.1111/j.1398-9995.2007.01543.x
70. Baldassarre ME, Laforgia N, Fanelli M et al. Lactobacillus GG improve recovery in infants with blood in the stools and presumptive allergic colitis compared with extensively hydrolyzed formula alone. J Pediatr 2010; 156: 397–401.
71. Berni Canani R, Di Costanzo M, Bedogni G et al. Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG reduces the occurrence of other allergic manifestations in children with cow’s milk allergy: 3-year randomized controlled trial. J Allergy Clin Immunol 2017; 139 (6): 1906–13. DOI: 10.1016/j.jaci.2016.10.050
72. Qamer S, Deshmukh M, Patole S. Probiotics for cow’s milk protein allergy: a systematic review of randomized controlled trials. Eur J Pediatr 2019; 178 (8): 1139–49. DOI: 10.1007/s00431-019-03397-6
73. Nase L, Hatakka K, Savilahti E et al. Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. Caries Res 2001; 35 (6): 412–20.
74. Schwendicke F, Dörfer C, Kneist S et al. Cariogenic Effects of Probiotic Lactobacillus rhamnosus GG in a Dental Biofilm Model. Caries Res 2014; 48 (3): 186–92. DOI: 10.1159/000355907
75. Gungor OE, Kirzioglu Z, Kivanc M. Probiotics: can they be used to improve oral health? Benef Microb 2015; 6 (5): 647–56. DOI: 10.3920/bm2014.0167
76. Knip M, Siljander H. The role of the intestinal microbiota in type 1 diabetes mellitus. Nat Rev Endocrinol 2016; 12: 154–67. DOI: 10.1038/nrendo.2015.218
77. Vatanen T, Franzosa EA, Schwager R et al. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. Nature 2018; 562 (7728): 589–94. DOI: 10.1038/s41586-018-0620-2
78. Groele L, Szajewska H, Szypowska A. Effects of Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 on beta-cell function in children with newly diagnosed type 1 diabetes: protocol of a randomised controlled trial. BMJ Open 2017; 7 (10): e017178. DOI: 10.1136/bmjopen-2017-017178
79. Abstracts for the 44th Annual Meeting of the International Society for Pediatric and Adolescent Diabetes (ISPAD), 11–14 October 2018, Hyderabad, India, Vol. 19, Issue S26: 33. doi.org/10.1111/pedi.12745
________________________________________________
2. Segers ME, Lebeer S. Towards a better understanding of Lactobacillus rhamnosus GG – host interactions. Microbial Cell Factories 2014; 13 (Suppl. 1): 7. DOI: 10.1186/1475-2859-13-s1-s7
3. Lu R, Fasano S, Madayiputhiya N et al. Isolation, Identification, and Characterization of Small Bioactive Peptides From Lactobacillus GG Conditional Media That Exert Both Anti-Gram-negative and Gram-positive Bactericidal Activity. J Pediatr Gastroenterol Nutr 2009; 49 (1): 23–30. DOI: 10.1097/mpg.0b013e3181924d1e
4. Vélez MP, Petrova MI, Lebeer S et al. Characterization of MabA, a modulator of Lactobacillus rhamnosus GG adhesion and biofilm formation. FEMS Immunol Med Microbiol 2010; 59 (3): 386–98. DOI: 10.1111/j.1574-695x.2010.00680.x
5. Landersjo C, Yang Z, Huttunen E, Widmalm G. Structural studies of the exopolysaccharide produced by Lactobacillus rhamnosus strain GG (ATCC 53103). Biomacromolecules 2002; 3: 880–4.
6. Wang Y, Liu L, Moore DJ et al. An LGG-derived protein promotes IgA production through upregulation of APRIL expression in intestinal epithelial cells. Mucosal Immunol 2016; 10 (2): 373–84. DOI: 10.1038/mi.2016.57
7. Claes IJ, Segers ME, Verhoeven TL et al. Lipoteichoic acid is an important microbe-associated molecular pattern of Lactobacillus rhamnosus GG. Microb Cell Fact 2012; 11: 161. DOI: 10.1186/1475-2859-11-161
8. Van Baarlen P, Troost FJ, Van der Meer C et al. Human mucosal in vivo transcriptome responses to three lactobacilli indicate how probiotics may modulate human cellular pathways. PNAS 2011; 108: 4562–9. DOI: 10.1073/pnas.1000079107
9. Bron PA, van Baarlen P, Kleerebezem M. Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. Nature Rev Microbiol 2011; 10 (1): 66–78. DOI: 10.1038/nrmicro2690
10. Korterink J, Devanarayana NM, Rajindrajith S et al. Childhood functional abdominal pain: mechanisms and management. Nat Rev Gastroenterol Hepatol 2015; 12 (3): 159–71. https: //doi.org/10.1038/nrgastro.2015.21
11. GBD Diarrhoeal Diseases Collaborators. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study. Lancet Infect Dis 2017; 17: 909–48. Erratum in: Lancet Infect Dis 2017; 17: 897.
12. Huang J, Bousvaros A, Lee J et al. Efficacy of probiotic use in acute diarrhea in children, a meta-analysis. Dig Dis Sci 2002; 47 (11): 2625–34.
13. Guarino A, Ashkenazi S, Gendrel D et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr 2014; 59: 132–52.
14. Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. Cochrane Database System Rev 2010. Issue 11. Art. No.: CD003048. DOI: 10.1002/14651858.CD003048.pub3
15. Szajewska H, Kołodziej M, Gieruszczak‐Białek D et al. Systematic review with meta‐analysis: Lactobacillus rhamnosus GG for treating acute gastroenteritis in children – a 2019 update. Aliment Pharmacol Ther 2019; 49: 1376–84.
16. Arvola T, Laiho K, Torkkeli S et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics 1999; 104: 64.
17. Johnston BC, Supina AL, Vohra S. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. CMAJ 2006; 175 (4): 377–83.
18. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101: 812–22.
19. Johnston BC, Goldenberg JZ, Vandvik PO et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2011; 11: CD004827. DOI: 10.1002/14651858.CD004827.pub3
20. Goldenberg JZ, Lytvyn L, Steurich J et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2015; 12: CD004827.
21. Szajewska H, Canani RB, Guarino A et al. ESPGHAN Working Group for Probiotics Prebiotics. Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Children. J Pediatr Gastroenterol Nutr 2016; 62 (3): 495–506. DOI: 10.1097/MPG.0000000000001081
22. Guo Q, Goldenberg JZ, Humphrey C et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2019; 4: CD004827. DOI: 10.1002/14651858.CD004827.pub5
23. Abarca-Gómez L, Abdeen ZA, Hamid ZA et al. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet 2017; 390 (10113): 2627–42. DOI: 10.1016/S0140-6736 (17)32129-3
24. Kumar S, Kelly AS. Review of Childhood Obesity. Mayo Clinic Proceedings 2017; 92 (2): 251–65. DOI: 10.1016/j.mayocp.2016.09.017
25. Machado MV, Cortez-Pinto H. Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol 2012; 11: 440–9.
26. Frost G, Sleeth ML, Sahuri-Arisoylu M et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun 2014; 5: 3611.
27. Zhu L, Baker SS, Gill C et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 2013; 57: 601–9.
28. Zhang H, DiBaise JK, Zuccolo A et al. Human gut microbiota in obesity and after gastric bypass. P Natl Acad Sci USA 2009; 106: 2365–70.
29. Michail S, Lin M, Frey MR et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol 2014; 91 (2): 1–9. DOI: 10.1093/femsec/fiu002
30. Vajro P, Mandato C, Licenziati MR et al. Effects of Lactobacillus rhamnosus Strain GG in Pediatric Obesity-related Liver Disease. J Pediatr Gastroenterol Nutr 2011; 52 (6): 740–3. DOI: 10.1097/mpg.0b013e31821f9b85
31. Sharpton SR, Maraj B, Harding-Theobald E et al. Gut microbiome – targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Am J Clin Nutr 2019; 110 (1): 139–49. DOI: 10.1093/ajcn/nqz042
32. Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. Genome Med 2016; 8: 51.
33. Man WH, de Steenhuijsen Piters WAA, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nature Rev Microbiol 2017; 15 (5): 259–70. DOI: 10.1038/nrmicro.2017.14
34. Esposito S, Principi N. Impact of nasopharyngeal microbiota on the development of respiratory tract diseases. Eur J Clin Microbiol Infect Dis 2017; 37 (1): 1–7. DOI: 10.1007/s10096-017-3076-7
35. Hatakka K, Savilahti E, Ponka A et al. Effect of long-term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ 2001; 322 (7298): 1327.
36. Hojsak I, Snovak N, Abdovic S et al. Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: a randomized, double-blind, placebo-controlled trial. Clin Nutr 2010; 29 (3): 312–6.
37. Rautava S, Salminen S, Isolauri E. Specific probiotics in reducing the risk of acute infections in infancy – a randomised, double-blind, placebo-controlled study. Br J Nutr 2009; 101 (11): 1722–6.
38. Liu S, Hu P, Du X et al. Lactobacillus rhamnosus GG supplementation for preventing respiratory infections in children: a meta-analysis of randomized, placebo-controlled trials. Indian Pediatr 2013; 50: 377–81.
39. Hao Q, Dong BR, Wu T. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev 2015; 2: CD006895.
40. Laursen RP, Hojsak I. Probiotics for respiratory tract infections in children attending day care centers – a systematic review. Eur J Pediatr 2018; 177 (7): 979–94. DOI: 10.1007/s00431-018-3167-1
41. Kumpu M, Kekkonen RA, Kautiainen H et al. Milk containing probiotic Lactobacillus rhamnosus GG and respiratory illness in children: a randomized, double-blind, placebo-controlled trial. Eur J Clin Nutr 2012; 66: 1020–3. DOI: doi.org/10.1038/ejcn. 2012.62
42. Scott AM, Clark J, Julien B et al. Probiotics for preventing acute otitis media in children. Cochrane Database Syst Rev 2019; Issue 6. Art. No.: CD012941. DOI: 10.1002/14651858.CD012941.pub2
43. Van den Broek MFL, De Boeck I, Claes IJJ et al. Multifactorial inhibition of lactobacilli against the respiratory tract pathogen Moraxella catarrhalis. Benef Microb 2018; 9 (3): 429–39. DOI: 10.3920/bm2017.0101
44. Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database System Rev 2015; Issue 12. Art. No.: CD008772. DOI: 10.1002/14651858.cd008772.pub2
45. Kara SS, Volkan B, Erten I. Lactobacillus rhamnosus GG can protect malnourished children. Benef Microb 2019; 10 (3): 237–44. DOI: 10.3920/BM2018.0071
46. http: //raaci.ru/education/clinic_recomendations/97.html
47. Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med 2005; 352: 2314–24.
48. Mastrorilli C, Caffarelli C, Hoffmann-Sommergruber K. Food allergy and atopic dermatitis: Prediction, progression, and prevention. Pediatr Allergy Immunol 2017; 28 (8): 831–40. DOI: 10.1111/pai.12831
49. Zhao W, Ho H, Bunyavanich S. The Gut Microbiome in Food Allergy. Ann Allergy, Asthma Immunol 2018; 122 (3): 276–82. DOI: 10.1016/j.anai.2018.12.012
50. Pascal M, Perez-Gordo M, Caballero T et al. Microb Allergic Dis Front Immunol 2018; 9: 1584. DOI: 10.3389/fimmu.2018.01584
51. Cosenza L, Nocerino R, Di Scala C et al. Bugs for atopy: the Lactobacillus rhamnosus GG strategy for food allergy prevention and treatment in children. Benef Microb 2015; 6 (2): 225–32. DOI: 10.3920/bm2014.0158
52. Isolauri E. Studies on Lactobacillus GG in food hypersensitivity disorders. Nutr Today (Suppl.) 1996; 31: 285–315.
53. Kalliomaki M, Salminen S, Arvilommi H et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001; 357: 1076–9. DOI: 10.1016/S0140-6736 (00)04259-8
54. Kalliomaki M, Salminen S, Poussa T et al. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003; 361: 1869–71. DOI: 10.1016/S0140-6736 (03)13490-3
55. Kalliomaki M, Salminen S, Poussa T, Isolauri E. Probiotics during the first 7 years of life: a cumulative risk reduction of eczema in a randomized, placebo- controlled trial. J Allergy Clin Immunol 2007; 119: 1019–21. DOI: 10.1016/j. jaci.2006.12.608
56. Rautava S, Kalliomaki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immnomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol 2002; 109 (1): 119–21.
57. Kalliomäki M, Antoine JM, Herz U et al. Guidance for Substantiating the Evidence for Beneficial Effects of Probiotics: Prevention and Management of Allergic Diseases by Probiotics. J Nutr 2010; 140 (3): 713S–721S. DOI: 10.3945/jn.109.113761
58. Fiocchi A, Pawankar R, Cuello-Garcia C et al. World allergy organization-McMaster university guidelines for allergic disease prevention (GLAD-P): Probiotics. World Allergy Organ J 2015; 8 (1): 4.
59. Szajewska H, Horvath A. Lactobacillus rhamnosus GG in the Primary Prevention of Eczema in Children: A Systematic Review and Meta-Analysis. Nutrients 2018; 10 (9): 1319. DOI: 10.3390/nu10091319
60. Berni Canani R, Di Costanzo M, Pezzella V et al. The potential therapeutic efficacy of Lactobacillus GG in children with food allergies. Pharmaceuticals 2012; 5: 655–64.
61. Murch SH. Toll of allergy reduced by probiotics. Lancet 2001; 357: 1057–9.
62. Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. J Allergy Clin Immunol 1997; 99 (2): 179–85.
63. Isolauri E, Arvola T, Sutas Y et al. Probiotics in the management of atopic eczema. Clin Exp Allergy 2000; 30 (11): 1604–10.
64. Rosenfeldt V, Benfeldt E, Nielsen SD et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 2003; 111 (2): 389–95. DOI: 10.1067/mai.2003.389
65. Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic Bacteria in the Management of Atopic Disease: Underscoring the Importance of Viability. J Pediatr Gastroenterol Nutr 2003; 36 (2): 223–7. DOI: 10.1097/00005176-200302000-00012
66. Viljanen M, Savilahti E, Haahtela T et al. Probiotics in the treatment of atopic eczema/ dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy 2005; 60: 494–500. DOI: 10.1111/j.1398-9995.2004.00514.x
67. Brouwer ML, Wolt-Plompen SAA, Dubois AEJ et al. No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. Clin Exper Allergy 2006; 36 (7): 899–906. DOI: 10.1111/j.1365-2222.2006.02513.x
68. Fölster-Holst R, Müller F, Schnopp N et al. Prospective, randomized controlled trial on Lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis. Br J Dermatol 2006; 155 (6): 1256–61. DOI: 10.1111/j.1365-2133.2006.07558.x
69. Grüber C, Wendt M, Sulser C et al. Randomized, placebo-controlled trial of Lactobacillus rhamnosus GG as treatment of atopic dermatitis in infancy. Allergy 2007; 62 (11): 1270–6. DOI: 10.1111/j.1398-9995.2007.01543.x
70. Baldassarre ME, Laforgia N, Fanelli M et al. Lactobacillus GG improve recovery in infants with blood in the stools and presumptive allergic colitis compared with extensively hydrolyzed formula alone. J Pediatr 2010; 156: 397–401.
71. Berni Canani R, Di Costanzo M, Bedogni G et al. Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG reduces the occurrence of other allergic manifestations in children with cow’s milk allergy: 3-year randomized controlled trial. J Allergy Clin Immunol 2017; 139 (6): 1906–13. DOI: 10.1016/j.jaci.2016.10.050
72. Qamer S, Deshmukh M, Patole S. Probiotics for cow’s milk protein allergy: a systematic review of randomized controlled trials. Eur J Pediatr 2019; 178 (8): 1139–49. DOI: 10.1007/s00431-019-03397-6
73. Nase L, Hatakka K, Savilahti E et al. Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. Caries Res 2001; 35 (6): 412–20.
74. Schwendicke F, Dörfer C, Kneist S et al. Cariogenic Effects of Probiotic Lactobacillus rhamnosus GG in a Dental Biofilm Model. Caries Res 2014; 48 (3): 186–92. DOI: 10.1159/000355907
75. Gungor OE, Kirzioglu Z, Kivanc M. Probiotics: can they be used to improve oral health? Benef Microb 2015; 6 (5): 647–56. DOI: 10.3920/bm2014.0167
76. Knip M, Siljander H. The role of the intestinal microbiota in type 1 diabetes mellitus. Nat Rev Endocrinol 2016; 12: 154–67. DOI: 10.1038/nrendo.2015.218
77. Vatanen T, Franzosa EA, Schwager R et al. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. Nature 2018; 562 (7728): 589–94. DOI: 10.1038/s41586-018-0620-2
78. Groele L, Szajewska H, Szypowska A. Effects of Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 on beta-cell function in children with newly diagnosed type 1 diabetes: protocol of a randomised controlled trial. BMJ Open 2017; 7 (10): e017178. DOI: 10.1136/bmjopen-2017-017178
79. Abstracts for the 44th Annual Meeting of the International Society for Pediatric and Adolescent Diabetes (ISPAD), 11–14 October 2018, Hyderabad, India, Vol. 19, Issue S26: 33. doi.org/10.1111/pedi.12745
Авторы
И.Н. Захарова*, Е.Ю. Борзова, М.А. Симакова
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия
*zakharova-rmapo@yandex.ru
Russian Medical Academy of Continuous Professional Education, Moscow, Russia
*zakharova-rmapo@yandex.ru
ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия
*zakharova-rmapo@yandex.ru
________________________________________________
Russian Medical Academy of Continuous Professional Education, Moscow, Russia
*zakharova-rmapo@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.